Clinical trial
A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease
NCT07358546 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 13, 2026
- Completion date
- October 13, 2027
- Enrollment
- 32 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.